Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of aC-microtracer and therapeutic dose in cancer patients

L van Andel; H. Rosing; Z Zhang; L. Hughes; V Kansra; M Sanghvi; M. Tibben; A. Gebretensae; J H M Schellens; J H Beijnen

doi:10.1007/s00280-017-3474-7

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of aC-microtracer and therapeutic dose in cancer patients

L van Andel
, H. Rosing
, Z Zhang
, L. Hughes
, V Kansra
, M Sanghvi
, M. Tibben
, A. Gebretensae
, J H M Schellens
, J H Beijnen

Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute and MC Slotervaart, PO Box 90440, 1006 BK, Amsterdam, The Netherlands. [email protected].
Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute and MC Slotervaart, PO Box 90440, 1006 BK, Amsterdam, The Netherlands.
TESARO, Inc., Waltham, MA, USA.
Xceleron, Inc., A Pharmaron Company, Germantown, MD, USA.
Netherlands Cancer Institute

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The article ''Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a14C-microtracer and therapeutic dose in cancer patients'', written by L. van Andel, H. Rosing, Z. Zhang, L. Hughes, V. Kansra, M. Sanghvi, M. M. Tibben, A. Gebretensae, J. H. M. Schellens and J. H. Beijnen, was originally published electronically on the publisher's internet portal (currently SpringerLink) on 17th October 2017 without open access.

Original language	English
Pages (from-to)	47
Journal	Cancer Chemotherapy and Pharmacology
Volume	81
Issue number	1
Early online date	17 Oct 2017
DOIs	https://doi.org/10.1007/s00280-017-3474-7
Publication status	Published - Jan 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Published Erratum

Access to Document

10.1007/s00280-017-3474-7

andelFinal published version, 517 KB

Cite this

van Andel, L., Rosing, H., Zhang, Z., Hughes, L., Kansra, V., Sanghvi, M., Tibben, M., Gebretensae, A., Schellens, J. H. M., & Beijnen, J. H. (2018). Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of aC-microtracer and therapeutic dose in cancer patients. Cancer Chemotherapy and Pharmacology, 81(1), 47. https://doi.org/10.1007/s00280-017-3474-7

@article{dedb5f5be9be47d28a2994ab8954092c,

title = "Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of aC-microtracer and therapeutic dose in cancer patients",

abstract = "The article ''Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a14C-microtracer and therapeutic dose in cancer patients'', written by L. van Andel, H. Rosing, Z. Zhang, L. Hughes, V. Kansra, M. Sanghvi, M. M. Tibben, A. Gebretensae, J. H. M. Schellens and J. H. Beijnen, was originally published electronically on the publisher's internet portal (currently SpringerLink) on 17th October 2017 without open access.",

keywords = "Published Erratum",

author = "\{van Andel\}, L and H. Rosing and Z Zhang and L. Hughes and V Kansra and M Sanghvi and M. Tibben and A. Gebretensae and Schellens, \{J H M\} and Beijnen, \{J H\}",

year = "2018",

month = jan,

doi = "10.1007/s00280-017-3474-7",

language = "English",

volume = "81",

pages = "47",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

van Andel, L, Rosing, H, Zhang, Z, Hughes, L, Kansra, V, Sanghvi, M, Tibben, M, Gebretensae, A, Schellens, JHM & Beijnen, JH 2018, 'Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of aC-microtracer and therapeutic dose in cancer patients', Cancer Chemotherapy and Pharmacology, vol. 81, no. 1, pp. 47. https://doi.org/10.1007/s00280-017-3474-7

TY - JOUR

T1 - Correction to

T2 - Determination of the absolute oral bioavailability of niraparib by simultaneous administration of aC-microtracer and therapeutic dose in cancer patients

AU - van Andel, L

AU - Rosing, H.

AU - Zhang, Z

AU - Hughes, L.

AU - Kansra, V

AU - Sanghvi, M

AU - Tibben, M.

AU - Gebretensae, A.

AU - Schellens, J H M

AU - Beijnen, J H

PY - 2018/1

Y1 - 2018/1

N2 - The article ''Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a14C-microtracer and therapeutic dose in cancer patients'', written by L. van Andel, H. Rosing, Z. Zhang, L. Hughes, V. Kansra, M. Sanghvi, M. M. Tibben, A. Gebretensae, J. H. M. Schellens and J. H. Beijnen, was originally published electronically on the publisher's internet portal (currently SpringerLink) on 17th October 2017 without open access.

AB - The article ''Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a14C-microtracer and therapeutic dose in cancer patients'', written by L. van Andel, H. Rosing, Z. Zhang, L. Hughes, V. Kansra, M. Sanghvi, M. M. Tibben, A. Gebretensae, J. H. M. Schellens and J. H. Beijnen, was originally published electronically on the publisher's internet portal (currently SpringerLink) on 17th October 2017 without open access.

KW - Published Erratum

U2 - 10.1007/s00280-017-3474-7

DO - 10.1007/s00280-017-3474-7

M3 - Article

C2 - 29181573

SN - 0344-5704

VL - 81

SP - 47

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 1

ER -

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of aC-microtracer and therapeutic dose in cancer patients

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this